文献速递乳腺癌

OlympiAD最终总生存与耐受性结果:奥拉帕利对比医生选择化疗用于胚系BRCA突变且HER2阴性转移性乳腺癌患者

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
PubMed 文献 · Ann Oncol · 2019-01-01

OlympiAD III期随机开放标签研究纳入胚系BRCA突变且HER2阴性转移性乳腺癌患者,随机接受奥拉帕利片(300 mg bid)或医生选择化疗(卡培他滨、长春瑞滨或艾日布林)。最终总生存分析显示奥拉帕利组中位OS 19.3个月 vs 化疗组17.1个月(HR 0.90,95%CI 0.66-1.23;P=0.513),未达统计学显著改善;奥拉帕利总体耐受性良好,无累积毒性证据。

要点

  • 最终OS:奥拉帕利组中位19.3个月 vs 化疗组17.1个月,HR 0.90(95%CI 0.66-1.23;P=0.513),无统计学显著差异。
  • 预设亚组中,未接受过转移性化疗者OS HR 0.51(95%CI 0.29-0.90),接受过者为1.13(0.79-1.64)。
  • 奥拉帕利治疗期间不良事件多为低级别,因不良事件停药率4.9%,延长暴露未增加贫血风险。

核心结论

  • 奥拉帕利相比医生选择化疗未显著改善总生存,但在未接受过转移性化疗的患者中可能存在有意义的OS获益。
  • 奥拉帕利总体耐受性良好,延长暴露无累积毒性证据。

研究设计与样本

  • OlympiAD为III期随机对照开放标签研究(NCT02000622),纳入胚系BRCA1和/或BRCA2突变且HER2阴性转移性乳腺癌患者。
  • 患者随机接受奥拉帕利片300 mg每日两次或预先指定的医生选择化疗(卡培他滨、长春瑞滨或艾日布林)。
  • 共205例随机至奥拉帕利组,97例随机至医生选择化疗组;OS与安全性为次要终点。

主要发现

  • 数据成熟度64%时,奥拉帕利组中位OS 19.3个月 vs 医生选择化疗组17.1个月(HR 0.90,95%CI 0.66-1.23;P=0.513)。
  • 中位随访时间分别为奥拉帕利组25.3个月和医生选择化疗组26.3个月。
  • 预设亚组OS HR:既往未接受转移性化疗(一线)0.51(95%CI 0.29-0.90),既往接受过(二/三线)1.13(0.79-1.64)。
  • 受体状态亚组OS HR:三阴性0.93(95%CI 0.62-1.43),激素受体阳性0.86(0.55-1.36)。
  • 既往铂类亚组OS HR:有0.83(95%CI 0.49-1.45),无0.91(0.64-1.33)。

关键数值与推荐

  • 奥拉帕利组中位OS 19.3个月 vs 医生选择化疗组17.1个月,HR 0.90(95%CI 0.66-1.23;P=0.513)。
  • 既往未接受转移性化疗亚组OS HR 0.51(95%CI 0.29-0.90)。
  • 因不良事件停药率4.9%。

临床怎么用

  • 奥拉帕利治疗期间不良事件多为低级别,可通过支持治疗或剂量调整管理。
  • 延长奥拉帕利暴露未增加贫血发生风险。
  • 作者认为未接受过转移性化疗的患者中可能存在有意义的OS获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician's choice (TPC) in patients with a germline BRCA1 and/or BRCA2 mutation (BRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). We now report the planned final overall survival (OS) results, and describe the most common adverse events (AEs) to better understand olaparib tolerability in this population. PATIENTS AND METHODS: OlympiAD, a Phase III, randomized, controlled, open-label study (NCT02000622), enrolled patients with a germline BRCAm and HER2-negative mBC who had received ≤2 lines of chemotherapy for mBC. Patients were randomized to olaparib tablets (300 mg bid) or predeclared TPC (capecitabine, vinorelbine, or eribulin). OS and safety were secondary end points. RESULTS: A total of 205 patients were randomized to olaparib and 97 to TPC. At 64% data maturity, median OS was 19.3 months with olaparib versus 17.1 months with TPC (HR 0.90, 95% CI 0.66-1.23; P = 0.513); median follow-up was 25.3 and 26.3 months, respectively. HR for OS with olaparib versus TPC in prespecified subgroups were: prior chemotherapy for mBC [no (first-line setting): 0.51, 95% CI 0.29-0.90; yes (second/third-line): 1.13, 0.79-1.64]; receptor status (triple negative: 0.93, 0.62-1.43; hormone receptor positive: 0.86, 0.55-1.36); prior platinum (yes: 0.83, 0.49-1.45; no: 0.91, 0.64-1.33). Adverse events during olaparib treatment were generally low grade and manageable by supportive treatment or dose modification. There was a low rate of treatment discontinuation (4.9%), and the risk of developing anemia did not increase with extended olaparib exposure. CONCLUSIONS: While there was no statistically significant improvement in OS with olaparib compared to TPC, there was the possibility of meaningful OS benefit among patients who had not received chemotherapy for metastatic disease. Olaparib was generally well-tolerated, with no evidence of cumulative toxicity during extended exposure. Please see the article online for additional video content.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019. PMID: 30689707. doi:10.1093/annonc/mdz012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。